Adipose-Derived Stem Cell Market to Reach $3013.9 Million by 2030.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Adipose-derived Stem Cell Market By Cell type (Autologous and Allogeneic stem cells), Product Type (Cell Line, Culture Media, Media, Sera And Reagents), Disease Conditions (Cancer, Obesity, Wounds And Injuries, Cardiovascular Diseases, Musculoskeletol Diseases And Others), Application (Therapeutic, Research, Others ), End-User (Cell Banks & Tissue Banks, Research Laboratories And Academic institutes, Hospitals and Trauma centers and Other end user industries) -Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

According to the latest research by InsightAce Analytic, the global adipose-derived stem cell market is valued at US$ 1035.13 million in 2021, and it is expected to reach US$ 3013.93 million by 2030, with a CAGR of 13.05% during the forecast period of 2022-2030.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1360

The extraction of adult stem cells suitable for tissue engineering and regenerative medicine applications can now be accomplished using adipose tissue, which is a convenient, abundant, and stable source. Preclinical research on the isolation, characterization, cryopreservation, differentiation, and transplantation of newly isolated stromal vascular fraction cells and adherent, culture-expanded, adipose-derived stromal/stem cells in vitro and animal models has exploded in the past ten years. The richness of the ADSC plays a crucial role in the restorative abilities of fat grafting. It is necessary to follow an isolation protocol for separating ADSCs from adipose tissue, and quality, safety, and effectiveness should all be considered. According to research, ADSCs can boost revascularization, activate regional stem cell niches, lessen oxidative stress, and control immunological reactions. ADSC products are attractive regenerative cell therapies because they can be retrieved in significant quantities with minor damage to the donor site. As ADSCs become more valuable in clinical settings, the goal of making ADSCs that are good enough for clinical use becomes more critical. Several countries have noticed that the industry of cell therapies is growing and have put in place rules to make sure they are safe.

There are a number of key market drivers for the adipose-derived stem cell market, including increasing regulatory approvals for clinical trials of ADSCs medicines and increasing funding for the development of regenerative therapies. In addition, there has been a recent rise in the formation of strategic collaborations between research institutes and manufacturers to accelerate the process of discovering new drugs and isolating them.

It is possible that disease-causing bacteria, viruses, or other pathogens will be introduced into the processing phase of adipose-derived stem cell therapy, which can lead to an infection. This is a potential consequence of adipose-derived stem cell therapy. Additionally, there are some constraints regarding the preservation and delivery of the cells, both of which will be responsible for restraining the market's growth.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-01

The North American region will dominate the ADSC market. Consistently rising investments in research and development over the past decade bode well for rapid and widespread progress in this therapeutic field.
Major market players are Allocure, Inc., Celgene Corporation, Pluristem Therapeutics, Inc. (Pluri, Inc), Intrexon, Inc., Celleris SA, Tissue Genesis, Inc., Mesoblast Ltd., Cytori Therapeutics, Antria, Inc., ThermoFisher Scientific, American CrysoStem, Merck KGaA, and Other Prominent players.

Key Developments in the market
• In July 2022, The name change from Pluristem Therapeutics, Inc. to Pluri, Inc. reflects the company's goal of expanding the use of its cutting-edge 3D cell-based technology platform beyond the healthcare sector. Pluri's advanced technology will sustain the advancement of healthcare and pharmaceuticals.
• In Dec 2021, Pluristem and the pharmaceutical company, Innovare R&D teamed up to bring the ARDS programme linked to COVID-19 to Mexico. Innovare will initiate clinical sites and patient enrollment for the proposed clinical study in Mexico under the terms of the agreement. Innovare will provide the funding for the Mexican study and will acquire the PLX cells for the study from Pluristem.
• In Nov 2019, It was announced by Celgene that after the acquisition by Bristol Myers Squibb is finalized, Celgene intends to transfer the listing of its contingent value rights. After the deal was finalized, Celgene became a wholly owned subsidiary of Bristol-Myers Squibb Company, as stated in the merger agreement.
• In Aug 2019, The U.S. FDA approved INREBIC® (Fedratinib) as the first novel therapy for myelofibrosis patients in almost a decade. INREBIC offers patients a novel, once-daily oral treatment alternative for their uncommon bone marrow cancer.

Market Segmentation:
Global Adipose-derived Stem Cell Market, by Cell Type, 2022-2030 (Value US$ Mn)
• Autologous Stem Cells
• Allogeneic Stem Cells
Global Adipose-derived Stem Cell Market, by Product Type, 2022-2030 (Value US$ Mn)
• Cell Line
• Culture Media
• Media
• Sera
• Reagents
Global Adipose-derived Stem Cell Market, by Disease Indication, 2022-2030 (Value US$ Mn)
• Cancer
• Obesity
• Wounds and Injuries
• Cardiovascular diseases
• Musculoskeletal diseases
• Others
Global Adipose-derived Stem Cell Market, by Application, 2022-2030 (Value US$ Mn)
• Therapeutic
• Research
• Others
Global Adipose-derived Stem Cell Market, by End-user Industry, 2022-2030 (Value US$ Mn)
• Cell banks & Tissue banks
• Research laboratories and Academic institutes
• Hospitals and Trauma centers
• Others
Global Adipose-derived Stem Cell Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Adipose-derived Stem Cell Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Adipose-derived Stem Cell Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Adipose-derived Stem Cell Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Adipose-derived Stem Cell Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Adipose-derived Stem Cell Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1360

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.